Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
KCT0008001Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Samsung Medical Center. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0008001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008001.